Takeda Pharmaceutical: Looking Forward To Pending Approvals and Late Stage Pipeline in FY27
āTakeda Pharmaceutical reported lower FY26 revenue due to generic erosion, but expects growth in FY27 driven by new launches and core brands, with...
146 Views
Sumitomo Pharma (4506 JP): America Drives FY26, To Be Continued in FY27, Enzomenib in Pivotal Phase
āSumitomo Pharma sees strong revenue growth in FY26 driven by North America. Momentum to continue in FY27. Profits to see some downside on R&D cost...
132 Views
Japan Pharma - FY17e Earnings Preview (I)
Astellas Pharma Inc (4503 JP) - April 26, 2018FY18e potential guidanceĀ Moderate Xtandi and Tarceva growth and Vesicare US patent expiry led y-o-y...
272 Views
BBSP Equity Asia Weekly Research 10th January 2018
Mid Term Country Allocation (Tactical view) in terms of Relative Value vs MXAPā¢ HSCEI/MXAP ratio is moving in a range pattern. Therefore downgrade...
472 Views
Drugs Evolving Into 'Biological Software' to Boost Moribund Pharma Sector?
The global pharma and biotech sector has underperformed by about four points this year, and five over three years ā the divergence with other...
392 Views